Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes

[1]  M. Heckman,et al.  Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. , 2021, Transplantation and cellular therapy.

[2]  R. Foà,et al.  Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 , 2020, Haematologica.

[3]  M. Arcila,et al.  Transplant Characteristics and Outcomes of Philadelphia (Ph)-like Acute Lymphoblastic Leukemia (ALL) , 2020 .

[4]  A. Tefferi,et al.  Clinical utility of fluorescence in situ hybridization‐based diagnosis of BCR‐ABL1 like (Philadelphia chromosome like) B‐acute lymphoblastic leukemia , 2020, American journal of hematology.

[5]  J. Smadbeck,et al.  Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma. , 2019, Mayo Clinic proceedings.

[6]  M. Loh,et al.  Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. , 2018, Blood.

[7]  D. Berry,et al.  Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis , 2017, JAMA oncology.

[8]  C. Mullighan,et al.  Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. , 2017, Blood.

[9]  W. Hiddemann,et al.  Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis , 2017, Haematologica.

[10]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[11]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[12]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.